Market atlas / Incretins / Semaglutide
Semaglutide (GLP-1, healthspan)
repurposedpeptideglp1-receptor-agonismmetabolicweight-loss● body-weight● hba1c
Stage by geography
Same development stage across markets, but Japan reached it about 5 years before Israel.
signalpreclinfirst-in-humanRCTapprovedreal-worldconsumerUSUKCNJPCHSGILKRIN+1 stages
MarketsUS United States FDAUK United Kingdom MHRA / NICECN China NMPAIN India CDSCOJP Japan PMDACH Switzerland SwissmedicSG Singapore HSAIL Israel Ministry of HealthKR South Korea MFDS
What each market approved it for
| Market | Stage | Since | Indication / class / form |
|---|---|---|---|
| US | approved | not dated | class GLP-1 Receptor Agonist [EPC] |
| UK | approved | 2021-01-01 | indication Ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when… |
| CN | approved | not dated | not published |
| IN | RCT | 2014-08-04 | not published |
| JP | approved | 2018-03-23 | indication A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. |
| CH | approved | 2018-07-02 | indication Type 2 diabetes mellitus; slowing progression of chronic kidney disease |
| SG | approved | 2021-04-21 | form Injection, solution, subcutaneous, prescription only |
| IL | approved | 2023-04-23 | indication Adults Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight… |
| KR | approved | 2022-04-28 | class Diabetes agents [MFDS 03960] |
China registers · NMPA
What each NMPA register actually approved. Reference approval NMPA SJ20260020. Domestic generics vs imported originator.
13imported approvals
approval count only; per-product detail not captured
Biomarker trends
no biomarker readings yet
Studies
The studies on Semaglutide, what they found, in whom and how strongly, are on its evidence page, each linked to its source.
What the trials measure
Registered primary outcomes this development's trials are powered on, commonest first (ClinicalTrials.gov). What is measured, across markets.
| Registered primary endpoint | Markets measuring it |
|---|---|
| Improvement in liver fibrosis and no worsening of NASH (Yes/No) | IN, JP, KR, SG |
| Relative change in body mass index (BMI) | IL, IN |
| Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of… | IL, IN |
| Participants Who Achieve HbA1c <7.0% (53 mmol/Mol) ADA Target (Yes/no) | CH, KR |
| Change from baseline in Hemoglobin A1c (HbA1c) | JP, KR |
| Relative change in body weight | IN |
| Change in Glycated haemoglobin (HbA1c ) | CH |
| Change From Baseline in HbA1c (Glycosylated Haemoglobin) | CH |
| Gastrointestinal adverse events (GI-AEs) | IL |
| Change in HbA1c | IL |
Connections
Trajectory
2018
MarketJP: approved-other (PMDA-approved (Japan))
PMDA:semaglutide (2018-03-23) · machine-extracted
2018
MarketCH: approved-other (Swissmedic-authorised (Switzerland))
Swissmedic:semaglutid (2018-07-02) · machine-extracted
2021
MarketUK: approved-other (MHRA-authorised (UK), per eMC SmPC)
EMC:semaglutide (product 9748) · machine-extracted
2021
MarketSG: approved-other (HSA-registered (Singapore))
HSA:semaglutide (2021-04-21) · machine-extracted
2022
MarketKR: approved-other (MFDS-approved (South Korea))
MFDS:semaglutide (2022-04-28) · machine-extracted
2023
MarketIL: approved-other (Israel MoH-registered)
IsraelMoH:semaglutide (2023-04-23) · machine-extracted
Get into the weeds: raw observations + provenance
sema_in 2026-06-29 kind=geography_stage verify=M Semaglutide: registered phase 3 trials in India [NCT02128932] source NCT02128932 https://clinicaltrials.gov/study/NCT02128932 pmda__dev_semaglutide__JP 2026-07-13 kind=geography_stage verify=M PMDA-approved in Japan: Semaglutide (genetical recombination) (Ozempic Subcutaneous Injection 2 mg (Novo Nordisk Pharma Ltd.)), first approval 2018-03-23. [PMDA List of Approved Drugs] source PMDA:semaglutide (2018-03-23) https://www.pmda.go.jp/files/000281190.pdf swissmedic__dev_semaglutide__CH 2026-07-13 kind=geography_stage verify=M Swissmedic-authorised in Switzerland: semaglutidum (Ozempic DualDose, prefilled pen), first authorisation 2018-07-02. [Swissmedic list of authorised medicinal products] source Swissmedic:semaglutid (2018-07-02) https://www.swissmedic.ch/dam/swissmedic/en/dokumente/internetlisten/erweiterte_ham_ind.xlsx.download.xlsx/erweiterte_ham_ind.xlsx sema_edge_metf 2026-06-29 kind=edge verify=M both metabolic, GLP-1 agonism vs AMPK/insulin sensitization source NCT03574597 https://clinicaltrials.gov/study/NCT03574597 sema_facets 2026-06-29 kind=facets verify=M Semaglutide facets source NCT03574597 https://clinicaltrials.gov/study/NCT03574597 sema_uk 2026-07-14 kind=geography_stage verify=M UK marketing authorisation (MHRA), per the eMC SmPC: Ozempic 0.25 mg solution for injection in pre-filled pen [active substance: semaglutide], first authorised 2021-01-01. [electronic Medicines Compendium, medicines.org.uk] source EMC:semaglutide (product 9748) https://www.medicines.org.uk/emc/product/9748/smpc hsa__dev_semaglutide__SG 2026-07-13 kind=geography_stage verify=M HSA-registered in Singapore: Semaglutide (OZEMPIC 0.25MG, 0.5MG/DOSE SOLUTION FOR INJECTION IN PRE-FILLED PEN 1.34MG/ML), first registration 2021-04-21. [HSA Listing of Registered Therapeutic Products] source HSA:semaglutide (2021-04-21) https://data.gov.sg/datasets/d_767279312753558cbf19d48344577084/view mfds__dev_semaglutide__KR 2026-07-13 kind=geography_stage verify=M MFDS-approved in South Korea: Semaglutide (Ozempic Pre-filled Pen(Semaglutide)), first approval 2022-04-28. [MFDS drug product-approval list] source MFDS:semaglutide (2022-04-28) https://nedrug.mfds.go.kr/pbp/CCBGA01 israelmoh__dev_semaglutide__IL 2026-07-13 kind=geography_stage verify=M Registered in Israel (Israeli Drug Registry): SEMAGLUTIDE 0.68 MG / 1 ML (WEGOVY 0.25 MG), current registration 2023-04-23. [Israel MoH Drug Registry] source IsraelMoH:semaglutide (2023-04-23) https://israeldrugs.health.gov.il/ sema_cn 2026-06-29 kind=geography_stage verify=M NMPA-approved in China (semaglutide): 13 imported approval(s). Reference NMPA SJ20260020. source NMPA:NMPA SJ20260020 https://www.nmpa.gov.cn/datasearch/home-index.html ctsearch__CH__dev_semaglutide 2026-07-10 kind=geography_stage verify=M semaglutide: 16 registered trial(s) in CH, highest phase 3 [NCT05586802] source NCT05586802 https://clinicaltrials.gov/study/NCT05586802 ctsearch__IL__dev_semaglutide 2026-07-10 kind=geography_stage verify=M semaglutide: 30 registered trial(s) in IL, highest phase 3 [NCT01720446] source NCT01720446 https://clinicaltrials.gov/study/NCT01720446 ctsearch__JP__dev_semaglutide 2026-07-10 kind=geography_stage verify=M semaglutide: 53 registered trial(s) in JP, highest phase 2 [NCT06409130] source NCT06409130 https://clinicaltrials.gov/study/NCT06409130 ctsearch__KR__dev_semaglutide 2026-07-10 kind=geography_stage verify=M semaglutide: 24 registered trial(s) in KR, highest phase 3 [NCT03811574] source NCT03811574 https://clinicaltrials.gov/study/NCT03811574 ctsearch__SG__dev_semaglutide 2026-07-10 kind=geography_stage verify=M semaglutide: 3 registered trial(s) in SG, highest phase 3 [NCT04822181] source NCT04822181 https://clinicaltrials.gov/study/NCT04822181 openfda__NDA209637__US 2026-07-13 kind=geography_stage verify=M FDA-approved in the US (SEMAGLUTIDE); approved, marketed [NDA209637] source NDA209637 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=NDA209637